Department of Urology, Kochi Medical School, Nankoku, Kochi, Japan.
Cancer. 2012 Feb 15;118(4):1062-74. doi: 10.1002/cncr.26378. Epub 2011 Jul 19.
This study was undertaken to evaluate the clinical value of photodynamic diagnosis (PDD) with intravesical and oral instillation of 5-aminolevulinic acid (ALA) (ALA-PDD), and transurethral resection of bladder tumor (TURBT) guided by ALA-PDD (PDD-TURBT) for nonmuscle invasive bladder cancer.
Of all 210 cases, 75 underwent PDD with intravesically applied ALA, and 135 cases underwent PDD with orally applied ALA. Diagnostic accuracy was evaluated by comparing the level on images of ALA-induced fluorescence with the pathological result. PDD-TURBT was performed in 99 completely resectable cases corresponding to 210 ALA-PDD cases. To evaluate the abilities of PDD-TURBT, survival analysis regarding intravesical recurrence was retrospectively compared with the historical control cases that underwent conventional TURBT.
The diagnostic accuracy and capability of ALA-PDD were significantly superior to those of conventional endoscopic examination. Moreover, 72.1% of flat lesions, including dysplasia and carcinoma in situ, could be detected only by ALA-PDD. The recurrence-free survival rate in the cases that underwent PDD-TURBT was significantly higher than that of conventional TURBT. Moreover, multivariate analysis revealed that the only independent factor contributing to improving prognosis was PDD-TURBT (hazard ratio, 0.578; P = .012). Regardless of the ALA administration route, there was no significant difference in diagnostic accuracy, ability of PDD, or recurrence-free survival. All procedures were well tolerated by all patients without any severe adverse events.
This multicenter study is likely to be biased, because it is limited by the retrospective analysis. This study suggests that regardless of the ALA administration route, ALA-PDD and PDD-TURBT are remarkably helpful in detection and intraoperative navigation programs.
本研究旨在评估经膀胱和口服 5-氨基酮戊酸(ALA)行光动力诊断(PDD)(ALA-PDD),以及 ALA-PDD 引导下经尿道膀胱肿瘤切除术(TURBT)(PDD-TURBT)治疗非肌层浸润性膀胱癌的临床价值。
210 例患者中,75 例行膀胱内 ALA-PDD,135 例行口服 ALA-PDD。通过比较 ALA 诱导荧光图像的水平与病理结果来评估诊断准确性。99 例完全可切除病例(210 例 ALA-PDD 病例)行 PDD-TURBT。为评估 PDD-TURBT 的能力,回顾性比较了行传统 TURBT 的历史对照病例的膀胱内复发生存分析。
ALA-PDD 的诊断准确性和能力明显优于传统内镜检查。此外,72.1%的平坦病变,包括发育不良和原位癌,只能通过 ALA-PDD 检测到。行 PDD-TURBT 的病例无复发生存率明显高于行传统 TURBT 的病例。此外,多因素分析显示,唯一能改善预后的独立因素是 PDD-TURBT(风险比,0.578;P=0.012)。无论 ALA 给药途径如何,诊断准确性、PDD 能力或无复发生存率均无显著差异。所有患者均能耐受所有程序,无严重不良事件。
本多中心研究可能存在偏倚,因为它受到回顾性分析的限制。本研究表明,无论 ALA 给药途径如何,ALA-PDD 和 PDD-TURBT 均有助于检测和术中导航。